GANODERMA LUCIDUM EKSTRAKTINING GASTROENTEROLOGIK KASALLIKLARDA QO‘LLANILISHI

Qodirova Saodat Rahimjonovna

Tibbiyot xodimlarining kasbiy malakasini rivojlantirish markazi Gastroenterologiya va fizioterapiya kafedrasi dotsenti

https://orcid.org/0009-0009-0720-7702

Keywords: Ganoderma lucidum, gastroenterologiya, disbioz, immunitet, antioksidant, mikrobiotsenoz, yara kasalligi, probiotik.

---

Abstract

Annotatsiya. Ushbu ilmiy tezisda Ganoderma lucidum ekstraktining gastroenterologik kasalliklarda, xususan ichak disbiozi bilan kechuvchi yara kasalliklarida qo‘llanilish samaradorligi o‘rganildi. Tadqiqot davomida ekstraktning ichak mikrobiotsenozi, immunologik holat, antioksidant tizim va bemorlarning psixoemotsional ko‘rsatkichlariga ta’siri baholandi. Natijalar shuni ko‘rsatdiki, Ganoderma lucidum ekstrakti ichak mikroflorasini normallashtiradi, yallig‘lanish mediatorlarini kamaytiradi hamda immun tizim faoliyatini yaxshilaydi. Shuningdek, antioksidant faollikning ortishi va bemorlarning hayot sifatining yaxshilanishi kuzatildi. Olingan ma’lumotlar Ganoderma lucidum ekstraktining gastroenterologik patologiyalarni kompleks davolashda istiqbolli vosita ekanligini tasdiqlaydi.

---

References

1. Soll A.H. Peptic ulcer and its complications // Sleisenger and Fordtran's Gastrointestinal and Liver Disease. - Philadelphia-Londom-Toronto-Montreal-Sydney-Tokyo,2018. - Vol.1. - P. 620-678

2. Stereo-selective metabolism of omeprazole by human cytochrome P450 enzymes / A. Abelo, T.B. Andersson, M. Antonsson et al // Drug. Metab. Dispos.-2020. -Vol. 28.- № 8. P. 966-972

3. Successful H.pylori eradication incorporating a one-week antibiotic regimen/ N. Hudson, WG. Brydon, MA. Eastwood et al.// Aliment. Pharmacol. Ther. - 2015. - №9. - P. 47-50.

4. Suzuki S., Esaki M., Kusano C., et al. Vonoprazan-based triple therapy vs PPI-based triple as first-line: Randomized trials in Japan // Gut. – 2017. – Vol. 66. – № 9. – P. 1724–1732.

5. Talley N.J., Lenables V.T., Green J.R. et al Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months / // Eur. J. Gastroenterol. Hepatol.-2012.- Vol. 14.- № 8.- P. 857-863